Lydia Abad-Franch

Lydia Abad-Franch, listed as board member, appears in our data through filings on Swedish Orphan Biovitrum AB (publ) shares, published by Finansinspektionen. We count 7 filings; the first trade dates from 10 June 2024 and the latest from 12 June 2026.

On the open market, the record shows 1 purchase worth €917k and 3 sales worth €1.8M. The net balance comes to €847k on the selling side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 3 share grants.

Most recently, on 16 June 2026, the filings show a share grant in Swedish Orphan Biovitrum AB (publ). The latest purchase dates back some time: it was published 378 days ago, on 27 October 2025. The median gap between a trade and its publication by Finansinspektionen is 3 days. The regulation allows three business days to notify a trade (MAR article 19). Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from Finansinspektionen disclosures alone and does not predict where the share price will go.